Health Care·Biotechnology·$185.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.09 | N/A | +1.34% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $4.09 | N/A | +1.34% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management expressed confidence in the company's strategic direction. They emphasized the importance of innovation and market positioning.
Management highlighted strong performance in key therapeutic areas.
They noted ongoing investments in R&D to drive future growth.
Amgen's earnings report shows a positive surprise in EPS, indicating better-than-expected profitability. The stock reacted modestly, rising by 0.32%, likely reflecting investor confidence in the company's ongoing strategies and performance in key areas. However, the lack of revenue data and guidance leaves some uncertainty about future growth prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
KONINKLIJKE PHILIPS ADR
Jan 30, 2023